Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus LORAZEPAM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus LORAZEPAM PRESERVATIVE FREE.
DORAL vs LORAZEPAM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and producing sedative, anxiolytic, anticonvulsant, and muscle relaxant effects.
15-30 mg orally at bedtime, maximum 60 mg/day.
0.5-2 mg orally every 6-8 hours as needed; maximum 4 mg/day. IV: 0.044 mg/kg (max 4 mg) every 6-8 hours for acute anxiety or sedation.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life: 12–14 hours (range 10–20 h). Clinically, no active metabolites; accumulation minimal at standard dosing intervals.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Renal: ~88% as glucuronide conjugates; <1% unchanged. Fecal: ~7%. Biliary: minor.
Category C
Category D/X
Benzodiazepine
Benzodiazepine